<DOC>
	<DOCNO>NCT01696565</DOCNO>
	<brief_summary>The objective Phase I/II study : 1 . To find maximum tolerate dose ( MTD ) PG2 patient advance malignancy receive chemotherapy define `` Study Dose '' Phase II . 2 . To evaluate hematopoietic immunological response administer PG2 . Primarily study biological response PG2 , define WBC count study , secondarily study immunological factor , IL-2 , IL-6 , TGF-beta , G-CSF .</brief_summary>
	<brief_title>PG2 Phase I/II Clinical Study Intravenously Administered Patients With Advanced Malignancy</brief_title>
	<detailed_description>This study first step PG2 clinical development Taiwan order establish safety efficacy profile build basis large trial .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patient must malignancy metastatic recurrent disease . Patient must minimum thirteen day period elapse previous chemotherapy radiotherapy treatmentrelated toxicity subside . Patient must least 2 course chemotherapy treatment leave , minimum 13 day administration last dose chemotherapy PG2 start next course chemotherapy . Performance status 02 ECOG scale . Patient 's compliance geographic proximity allow adequate follow . Adequate bone marrow function chemotherapy Adequate liver renal function chemotherapy Written inform consent patient Woman childbearing potential use contraception method whole PG2 treatment course . After previous course chemotherapy , nadir WBC drop 1000 3000/ mm3 ( phase II ) . PG2 skin test positive . Active infection Breast feeding Prior radiotherapy 30 % bone marrow involve . Pregnant woman Bone marrow transplantation brain disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>myelosuppression</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Astragalus membranaceus</keyword>
	<keyword>hematopoietic response</keyword>
</DOC>